Evoked potentials are useful for diagnosis of neuromyelitis optica spectrum disorder

被引:11
|
作者
Ohnari, Keiko [1 ]
Okada, Kazumasa [1 ]
Takahashi, Toshiyuki [2 ,3 ]
Mafune, Kosuke [4 ]
Adachi, Hiroaki [1 ]
机构
[1] Univ Occupat & Environm Hlth, Sch Med, Dept Neurol, Kitakyushu, Fukuoka 8078555, Japan
[2] Tohoku Univ, Sch Med, Dept Neurol, Seiryomachi, Sendai, Miyagi 9808574, Japan
[3] Yonezawa Natl Hosp, Dept Neurol, 26100-1 Misawa, Yonezawa, Yamagata 9921202, Japan
[4] Univ Occupat & Environm Hlth, Sch Med, Inst Ind Ecol Sci, Dept Mental Hlth, Kitakyushu, Fukuoka 8078555, Japan
关键词
Neuromyelitis optica; Relapsing-remitting multiple sclerosis; Visual evoked potentials; Auditory brainstem responses; Motor evoked potentials; CERVICAL-SPINAL CORD; MULTIPLE-SCLEROSIS; DISABILITY; CRITERIA; ABNORMALITIES;
D O I
10.1016/j.jns.2016.02.060
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Neuromyelitis optica spectrum disorder (NMOSD) has been differentiated from relapsing-remitting multiple sclerosis (RRMS) by clinical, laboratory, and pathological findings, including the presence of the anti-aquaporin 4 antibody. Measurement of evoked potentials (EPs) is often used for the diagnosis of RRMS, although the possibility of applying EPs to the diagnosis of NMOSD has not been investigated in detail. Eighteen patients with NMOSD and 28 patients with RRMS were included in this study. The patients' neurological symptoms and signs were examined and their EPs were recorded. Characteristic findings were absence of visual evoked potentials and absence of motor evoked potentials in the lower extremities in patients with NMOSD, and a delay in these potentials in patients with RRMS. Most patients with NMOSD did not present abnormal subclinical EPs, whereas many patients with RRMS did. None of the patients with NMOSD showed abnormalities in auditory brainstem responses. NMOSD can be differentiated from RRMS by EP data obtained in the early stages of these diseases. (C) 2016 Elsevier B.V. All rights reserved.
引用
收藏
页码:97 / 101
页数:5
相关论文
共 50 条
  • [31] Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder
    Fung, Simon
    Shirley, Matt
    CNS DRUGS, 2023, 37 (04) : 363 - 370
  • [32] Inebilizumab for treatment of neuromyelitis optica spectrum disorder
    Tullman, Mark J.
    Zabeti, Aram
    Vuocolo, Scott
    Dinh, Quinn
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2021, 11 (05) : 341 - 352
  • [33] Pregnancy outcomes in neuromyelitis optica spectrum disorder
    Vishnevetsky, A.
    Levy, M.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 140 - 140
  • [34] Satralizumab in the treatment of neuromyelitis optica spectrum disorder
    Duchow, Ankelien
    Bellmann-Strobl, Judith
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2021, 11 (01) : 49 - 59
  • [35] Cyclophosphamide treatment in Neuromyelitis Optica Spectrum Disorder
    Gulluoglu, H.
    Uysal, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 798 - 798
  • [36] Urinalysis in patients with neuromyelitis optica spectrum disorder
    Chen, Z. G.
    Huang, J.
    Fan, R.
    Weng, R. H.
    Shinohara, R. T.
    Landis, J. R.
    Chen, Y.
    Jiang, Y.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 (04) : 619 - 625
  • [37] Frequency of comorbidities in Neuromyelitis Optica spectrum disorder
    Barzegar, Mahdi
    Mirmosayyeb, Omid
    Nehzat, Nasim
    Vaheb, Saeed
    Shaygannejad, Vahid
    Asgari, Nasrin
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 48
  • [38] A new era for neuromyelitis optica spectrum disorder
    Silbermann, Elizabeth
    Bourdette, Dennis
    LANCET, 2019, 394 (10206): : 1304 - 1305
  • [39] Neuromyelitis Optica Spectrum Disorder Presented with Pseudoathetosis
    Seok, Hung Youl
    Eun, Mi-Yeon
    Jang, Seong Hwa
    You, Sooyeoun
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (03) : 419 - 419
  • [40] Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder
    Simon Fung
    Matt Shirley
    CNS Drugs, 2023, 37 : 363 - 370